News | July 20, 2022
GSK’s Haleon begins trading in LSE
Completion of the demerger of Haleon and share consolidation of GSK
Completion of the demerger of Haleon and share consolidation of GSK
The award was presented to her during a virtual ceremony on the occasion of 8th International Day of Yoga on 21st June 2022.
First and only PARP inhibitor to improve invasive disease-free survival in patients
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
AstraZeneca also played a critical role in the global response to COVID-19.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
The proposed demerger is the most significant corporate change for GSK in the last 20 years
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
Subscribe To Our Newsletter & Stay Updated
